NASDAQ · ABUS
Healthcare · Biotechnology
$5.05
Down-$0.01 (-0.20%)
Updated Sep 17, 2026, 8:33 AM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ABUS closed at $5.05 after 20 trading sessions, up 1.41% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $5.06 | $5.0891 | $5.02 | $5.05 | 4.01M |
| Sep 15, 2026 | $5.11 | $5.15 | $5.03 | $5.06 | 4.05M |
| Sep 14, 2026 | $5.12 | $5.16 | $5.095 | $5.13 | 3.8M |
| Sep 11, 2026 | $5.17 | $5.175 | $5.11 | $5.12 | 1.85M |
| Sep 10, 2026 | $5.11 | $5.165 | $5.10 | $5.12 | 2.45M |
| Sep 9, 2026 | $5.16 | $5.23 | $5.125 | $5.17 | 5.51M |
| Sep 8, 2026 | $5.10 | $5.20 | $5.08 | $5.18 | 5.29M |
| Sep 4, 2026 | $5.09 | $5.17 | $5.09 | $5.15 | 5.2M |
| Sep 3, 2026 | $5.11 | $5.1541 | $5.095 | $5.12 | 3.23M |
| Sep 2, 2026 | $5.10 | $5.19 | $5.09 | $5.10 | 2.98M |
| Sep 1, 2026 | $5.05 | $5.10 | $5.05 | $5.09 | 2.61M |
| Aug 31, 2026 | $5.05 | $5.105 | $4.992 | $5.08 | 3.56M |
| Aug 28, 2026 | $5.15 | $5.19 | $5.05 | $5.07 | 4.77M |
| Aug 27, 2026 | $5.16 | $5.215 | $5.14 | $5.17 | 3.58M |
| Aug 26, 2026 | $5.19 | $5.23 | $5.175 | $5.19 | 4.6M |
| Aug 25, 2026 | $5.25 | $5.26 | $5.13 | $5.20 | 8.91M |
| Aug 24, 2026 | $5.18 | $5.28 | $5.1702 | $5.20 | 18.14M |
| Aug 21, 2026 | $5.20 | $5.45 | $5.09 | $5.21 | 18.07M |
| Aug 20, 2026 | $4.92 | $4.96 | $4.74 | $4.77 | 1.27M |
| Aug 19, 2026 | $4.83 | $5.18 | $4.83 | $4.98 | 3.43M |
The latest Smart Investors Daily articles mentioning ABUS.
ABUS research
Company profile and research snapshot.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 14, 2025 | Chardan Capital | Buy | — |
| Aug 11, 2025 | Chardan Capital | Buy | — |
| Mar 28, 2025 | Chardan Capital | Buy | — |
| Jan 21, 2025 | HC Wainwright & Co. | Buy | — |
| Nov 20, 2024 | Chardan Capital | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 13, 2026
Roivant Sciences outlook: LISRAYA approval strengthens revenue, while brepocitinib and mosliciguat could expand immunology/pulmonary franchises. Click for more on ROIV stock.
Yahoo · Aug 24, 2026
WARMINSTER, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the commencement of a modified “Dutch Auction” tender offer to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”) at a price of not less than US$5.00 and not more than US $5.75 per Share, less any applicable withholding taxes and without inter
Yahoo · Aug 21, 2026
Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 1.4% and the S
Yahoo · Aug 21, 2026
Arbutus Biopharma Corporation (NASDAQ:ABUS) shares climbed 10. 3% in premarket trading on Friday after the biotechnology company announced plans to repurchase up to $230 million of its common stock through a modified Dutch auction tender offer.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ABUS.
